文献速递临床微生物

预测肠杆菌科临床分离株对头孢洛林体外敏感性的潜在β-内酰胺替代物分析

Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae.
PubMed 文献 · J Clin Microbiol · 2018-03-26

该研究评估了6种β-内酰胺类药物作为头孢洛林替代物,预测543株肠杆菌科临床分离株体外敏感性的可行性。所有潜在替代物的极重大误差率为16.3%至56.6%,远超CLSI和FDA可接受的1.5%限值,未能找到可靠替代物。

要点

  • 6种β-内酰胺替代物预测头孢洛林敏感性的极重大误差率均远超可接受限值。
  • 商业药敏试验设备缺乏头孢洛林测试 panel,实验室需替代方法。
  • 亟需加速将新型抗菌药物纳入商业药敏试验设备。

核心结论

  • 未发现能可靠预测肠杆菌科对头孢洛林体外敏感性的β-内酰胺替代物。

研究设计与样本

  • 评估6种β-内酰胺类药物作为头孢洛林替代物,测试543株肠杆菌科临床分离株,菌株选择模拟2013年AWARE全球监测研究中头孢洛林MIC分布。

主要发现

  • 所有6种潜在替代物的极重大误差率为16.3%至56.6%,远超CLSI和FDA设定的1.5%限值。

关键数值与推荐

  • 极重大误差率可接受限值为1.5%,由CLSI和FDA设定。

临床怎么用

  • 实验室在商业设备可测试头孢洛林前,需采用纸片扩散法或梯度条法进行药敏试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ceftaroline fosamil was approved by the United States Food and Drug Administration in 2010 and by the European Medicines Agency in 2012. As of April 2017, only one commercial antimicrobial susceptibility testing device offered a Gram-negative panel that included ceftaroline. This circumstance is unfortunate, as many clinical microbiology laboratories rely solely on commercial devices to generate in vitro antimicrobial susceptibility testing results for common bacterial pathogens. In lieu of device-based testing of clinical isolates of Enterobacteriaceae, laboratories wishing to test ceftaroline must either opt for disk diffusion testing or use a gradient strip; however, both alternatives interrupt laboratory workflow and require additional labor and expense. Identification of a reliable surrogate β-lactam to predict in vitro susceptibility to ceftaroline may offer another interim solution as laboratories await availability of ceftaroline for testing on their commercial devices. We tested six β-lactams (aztreonam, ceftazidime, ceftriaxone, cefotaxime, cefoxitin, and cefpodoxime) as potential surrogates for ceftaroline against a collection of 543 clinical isolates of Enterobacteriaceae selected to approximate the distribution of ceftaroline MICs observed in AWARE global surveillance studies conducted in 2013. All six potential surrogates generated very major error rates of 16.3% to 56.6%, far exceeding the accepted limit of 1.5% set by the Clinical and Laboratory Standards Institute (CLSI) and the United States Food and Drug Administration (FDA) Center for Devices and Radiological Health. Failure to identify a reliable surrogate to predict in vitro susceptibility and resistance to ceftaroline for clinical isolates of Enterobacteriaceae underscores the need for expedited addition of newer antimicrobial agents to commercial antimicrobial susceptibility testing devices.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Hackel MA, Iaconis JP, Karlowsky JA, et al. Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae. J Clin Microbiol. 2018. PMID: 29436424. doi:10.1128/JCM.01892-17

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。